<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1750-9378-4-2</ui>
   <ji>1750-9378</ji>
   <fm>
      <dochead>Letter to the Editor</dochead>
      <bibl>
         <title>
            <p>Antiviral therapy in acute viral hepatitis B: why and when</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Morelli</snm>
               <fnm>Giuseppe</fnm>
               <insr iid="I1"/>
               <email>pinomorelli25@libero.it</email>
            </au>
            <au id="A2" ca="yes">
               <snm>Perrella</snm>
               <fnm>Alessandro</fnm>
               <insr iid="I1"/>
               <insr iid="I2"/>
               <email>alexperrel@virgilio.it</email>
            </au>
            <au id="A3">
               <snm>Sbreglia</snm>
               <fnm>Costanza</fnm>
               <insr iid="I1"/>
               <email>drcosty@libero.it</email>
            </au>
            <au id="A4">
               <snm>Bellopede</snm>
               <fnm>Pasquale</fnm>
               <insr iid="I1"/>
               <email>pbellop@libero.it</email>
            </au>
            <au id="A5">
               <snm>Riccio</snm>
               <fnm>Vincenzo</fnm>
               <insr iid="I1"/>
               <email>oreste.perrella@ospedalecotugno.it</email>
            </au>
            <au id="A6">
               <snm>Perrella</snm>
               <fnm>Oreste</fnm>
               <insr iid="I1"/>
               <email>oreste.perrella@ospedalecotugno.it</email>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>VII Department of Infectious Diseases and Immunology, "D. Cotugno" Hospital, Naples, Italy</p>
            </ins>
            <ins id="I2">
               <p>"Liver Unit," A. Cardarelli Hospital, Naples, Italy</p>
            </ins>
         </insg>
         <source>Infectious Agents and Cancer</source>
         <issn>1750-9378</issn>
         <pubdate>2009</pubdate>
         <volume>4</volume>
         <issue>1</issue>
         <fpage>2</fpage>
         <url>http://www.infectagentscancer.com/content/4/1/2</url>
         <xrefbib>
            <pubidlist>
               <pubid idtype="pmpid">19149879</pubid>
               <pubid idtype="doi">10.1186/1750-9378-4-2</pubid>
            </pubidlist>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>30</day>
               <month>7</month>
               <year>2008</year>
            </date>
         </rec>
         <acc>
            <date>
               <day>16</day>
               <month>1</month>
               <year>2009</year>
            </date>
         </acc>
         <pub>
            <date>
               <day>16</day>
               <month>1</month>
               <year>2009</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2009</year>
         <collab>Morelli et al; licensee BioMed Central Ltd.</collab>
         <note>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</note>
      </cpyrt>
      <abs>
         <sec>
            <st>
               <p>Abstract</p>
            </st>
            <p>Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may develop either chronic HBV infection or, rarely, fulminant hepatitis.</p>
            <p>Therefore there are elderly patients with severe acute HBV hepatitis caractherized by high serum bilirubin levels >15 mmole/dl, international normalized ratio (INR) with value more than 1.6; these patients are caractherized by a severe outcome of HBV infection.</p>
            <p>As known, outcome of infection and the pathogenesis of liver diseases are determined by viral and host factors, such as T reg lymphocytes.</p>
            <p>T regs may be associated with a negative immune response such as an inhibition of gamma- IFN secretion.</p>
            <p>The impact of viral load on antiviral T cell responses may play a critical role in thaese patients, influencing disease persistence and immune response.</p>
            <p>Antiviral drugs could be useful in these patients determing a possible down -regulation of T regs.</p>
         </sec>
      </abs>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Letter to the editor</p>
         </st>
         <p>Dear Editor,</p>
         <p>Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may develop either chronic HBV infection or, rarely, fulminant hepatitis. <abbrgrp><abbr bid="B1">1</abbr></abbrgrp> The role of antivirals, such as lamivudine or entecavir, in acute HBV infection, has not been evaluated in controlled trials.</p>
         <p>Lamivudine administration shows an antiviral efficacy in patients with HbeAg positive and HbeAg negative.</p>
         <p>Among the patients with acute infection there are elderly subjects with severe course and severe outcome of HBV hepatitis.</p>
         <p>A logical hypothesis for these patients is that a rapid decrease in the HBVDNA levels trough the use of antiviral agents could result in a less intense host response against HBV virus.</p>
         <p>Today, increased knowledge of the virological and immunological events to HBV infection permits to define the mechanisms involved in viral clearance, persistence and disease severity.</p>
         <p>Outcome of infection and the pathogenesis of liver disease are determined by viral and host factors. <abbrgrp><abbr bid="B1">1</abbr></abbrgrp></p>
         <p>The impact of viral load on antiviral T-cell responses has been precisely characterized in animal models of viral infections: a sustained presence of viral antigens leads to virus specific T cell deletion <abbrgrp><abbr bid="B2">2</abbr></abbrgrp>.</p>
         <p>In HBV infection the frequency and function of circulatory and intrahepatic HBV specific CD8 T cells is inversely proportional to the level of HBV-DNA. <abbrgrp><abbr bid="B3">3</abbr></abbrgrp></p>
         <p>The immunological defects could be proportional to the level of HBV infection and inhibition of viral replication and through antiviral treatment it is possible to obtaine a partial restoration of HBV specific T cell immunity <abbrgrp><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr></abbrgrp> which is inadeguate in elderly patients. <abbrgrp><abbr bid="B6">6</abbr></abbrgrp></p>
         <p>Moreover recent studies have provided evidence that a population of specialized T cells are able to regulate the immune response.</p>
         <p>These cells reside mainly within a minor population of CD4 cells that express the phenotype marker CD 25. <abbrgrp><abbr bid="B7">7</abbr></abbrgrp></p>
         <p>They have been shown to suppress immunological responses against self and foreign antigens through suppressive cytokines.</p>
         <p>It is possible that CD4+ CD25+ T cells are responsible for the weak HBV specific T cell response in HBV infection and may inhibit the expansion and function of HBV specific CD8 T cells precluding HBV clearance.</p>
         <p>Some authors showed that the frequency of CD4+ CD25+ T cells positively correlate with HBVDNA load. <abbrgrp><abbr bid="B6">6</abbr></abbrgrp></p>
         <p>This result suggests that an increased level of T regs may be associated with a negative immune response, leading to poor viral clearance.</p>
         <p>Our hypothesis is that a decrease of HBV DNA load, determined by lamivudine treatment, determines a downregulation of T regs.</p>
         <p>T regs could be able suppressing the population and gamma IFN production, mediated by HbsAg.</p>
         <p>In summary, our findings suggest that it could be possible a marked increase in circulating Tregs in elderly patients with HBV infection.</p>
         <p>Taken together these data, it is possible that antiviral drugs might be useful in a selected group of old patients in which HBV may cause a severe form of acute hepatitis, caused by a decline of immunity and by the frequent presence of other morbidities.</p>
      </sec>
      <sec>
         <st>
            <p>Competing interests</p>
         </st>
         <p>The authors declare that they have no competing interests.</p>
      </sec>
      <sec>
         <st>
            <p>Authors' contributions</p>
         </st>
         <p>GM performed the study and wrote the article.</p>
         <p>AP and OP designed the study and reviewed the article.</p>
         <p>CS, PB and VR analized the clinical data for the study.</p>
      </sec>
   </bdy>
   <bm>
      <refgrp>
         <bibl id="B1">
            <title>
               <p>Chronic hepatitis B</p>
            </title>
            <aug>
               <au>
                  <snm>Lok</snm>
                  <fnm>AS</fnm>
               </au>
               <au>
                  <snm>McMahon</snm>
                  <fnm>BJ</fnm>
               </au>
            </aug>
            <source>Hepatology</source>
            <pubdate>2001</pubdate>
            <volume>34</volume>
            <fpage>1225</fpage>
            <lpage>41</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1053/jhep.2001.29401</pubid>
                  <pubid idtype="pmpid" link="fulltext">11732013</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B2">
            <title>
               <p>Direct ex vivo analysis of hepatitis B virus specific CD8+ T cells....with the control of infection</p>
            </title>
            <aug>
               <au>
                  <snm>Maini</snm>
                  <fnm>HK</fnm>
               </au>
               <au>
                  <snm>Boni</snm>
                  <fnm>C</fnm>
               </au>
               <au>
                  <snm>Oggs</snm>
                  <fnm>GS</fnm>
               </au>
            </aug>
            <source>Gastroenterology</source>
            <pubdate>1999</pubdate>
            <volume>117</volume>
            <fpage>1386</fpage>
            <lpage>96</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1016/S0016-5085(99)70289-1</pubid>
                  <pubid idtype="pmpid" link="fulltext">10579980</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B3">
            <title>
               <p>Hepatitis B</p>
            </title>
            <aug>
               <au>
                  <snm>Dusheinko</snm>
                  <fnm>G</fnm>
               </au>
            </aug>
            <source>J Hepatology</source>
            <pubdate>2003</pubdate>
            <volume>44</volume>
            <fpage>948</fpage>
            <lpage>89</lpage>
         </bibl>
         <bibl id="B4">
            <title>
               <p>Transient restoration R, of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B</p>
            </title>
            <aug>
               <au>
                  <snm>Boni</snm>
                  <fnm>C</fnm>
               </au>
               <au>
                  <snm>Penna</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Bertoletti</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Lamonaca</snm>
                  <fnm>V</fnm>
               </au>
               <au>
                  <snm>Rapti</snm>
                  <fnm>I</fnm>
               </au>
               <au>
                  <snm>Cavalli</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Cerioni</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Panebianco</snm>
                  <fnm>R</fnm>
               </au>
               <au>
                  <snm>Jenkins</snm>
                  <fnm>J</fnm>
               </au>
               <au>
                  <snm>Ferrari</snm>
                  <fnm>C</fnm>
               </au>
            </aug>
            <source>J Hepatol</source>
            <pubdate>2003</pubdate>
            <volume>39</volume>
            <fpage>595</fpage>
            <lpage>605</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1016/S0168-8278(03)00292-7</pubid>
                  <pubid idtype="pmpid" link="fulltext">12971971</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B5">
            <title>
               <p>Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity</p>
            </title>
            <aug>
               <au>
                  <snm>Rigopoulou</snm>
                  <fnm>EI</fnm>
               </au>
               <au>
                  <snm>Suri</snm>
                  <fnm>D</fnm>
               </au>
               <au>
                  <snm>Chokshi</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Mullerova</snm>
                  <fnm>I</fnm>
               </au>
               <au>
                  <snm>Rice</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Tedder</snm>
                  <fnm>RS</fnm>
               </au>
               <au>
                  <snm>Williams</snm>
                  <fnm>R</fnm>
               </au>
               <au>
                  <snm>Naoumov</snm>
                  <fnm>NV</fnm>
               </au>
            </aug>
            <source>Hepatology</source>
            <pubdate>2005</pubdate>
            <volume>42</volume>
            <fpage>1028</fpage>
            <lpage>36</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1002/hep.20888</pubid>
                  <pubid idtype="pmpid" link="fulltext">16250037</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B6">
            <title>
               <p>CD4+CD25+ T cells regulate virus- specific primary and memory CD8+ T cell responses</p>
            </title>
            <aug>
               <au>
                  <snm>Suvas</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Kumaraguru</snm>
                  <fnm>U</fnm>
               </au>
               <au>
                  <snm>Pack</snm>
                  <fnm>CD</fnm>
               </au>
               <au>
                  <snm>Lee</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Rouse</snm>
                  <fnm>BT</fnm>
               </au>
            </aug>
            <source>J Exp Med</source>
            <pubdate>2003</pubdate>
            <volume>198</volume>
            <fpage>889</fpage>
            <lpage>901</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="pmcid">2194203</pubid>
                  <pubid idtype="pmpid" link="fulltext">12975455</pubid>
                  <pubid idtype="doi">10.1084/jem.20030171</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B7">
            <title>
               <p>Noncytolytic control of viral infections by the innate and adaptive immune response</p>
            </title>
            <aug>
               <au>
                  <snm>Guidotti</snm>
                  <fnm>LG</fnm>
               </au>
               <au>
                  <snm>Chisari</snm>
                  <fnm>PV</fnm>
               </au>
            </aug>
            <source>Annu Rev immunol</source>
            <pubdate>2001</pubdate>
            <volume>19</volume>
            <fpage>65</fpage>
            <lpage>91</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1146/annurev.immunol.19.1.65</pubid>
                  <pubid idtype="pmpid" link="fulltext">11244031</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
      </refgrp>
   </bm>
</art>
